Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.


TSX:AEZS - Post by User

Bullboard Posts
Post by RetailRubeon Aug 22, 2010 9:04pm
625 Views
Post# 17373344

Options price hurting stock price

Options price hurting stock priceOn April 20, AEZ did a private placement with units sold at $1.35 which included options exercisable at $1.50.

On June 18, AEZ did another private placement with units sold at US$1.37 which also included options.  But this time, the options are exercisable at the same US$1.37.  The pricing of the options should cause selling pressure on the stock price.  This is because Fund Managers who participated in the private placement could sell other shares in AEZ they already held, hopefully getting close to $1.37 the stock was trading at on June 17th, and they would be left only with the options exercisable at $1.37.  In other words, they would get to participate in the upside of the stock with no invested capital.

Of course, as the Fund Managers started selling, the stock would start going down.  But it would still be worth their while to sell as long as the stock was above 98 cents US ($1.03 Cdn).  The company issued just under 9 million shares on June 18th.  Since early July, about 2 million shares have changed hands on the TMX.  I did not look up trading in the US.  The stock has declined to as low as Cdn$1.06.  The selling is almost all from "Anonymous".

My conclusion:  Friday's price should be about the bottom.  When the selling stops, I think the stock price will bounce back to the diluted price at the time of the June private placement, which would be about US$1.32.  However, since only 2 million of the 9 million shares have been sold so far, it could hover around Friday's level for a while.

I bought in early June, feeling safe that the April placement was the last of the dilution for a while.  Then the company surprise me with the mid-June placement and the sweet options.  The good news is they now have enough cash to last until early 2012.  But I still feel I got taken.

Bullboard Posts